priors.science/reviews/inflammatory-bowel-disease

Inflammatory Bowel Disease

The current evidence on 23 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

23claims tracked
248primary papers reviewed
9 Aug 2026latest evidence review
Weeklyre-scored against new papers
5 Established · 12 Likely · 6 Uncertain · 0 Doubtful  |  four-reviewer panel · PICO Framework
ClaimStandingEvidence certaintyCorpus
Anti-TNF induces remission in Crohn's diseaseAnti TNFEstablished94%20
Ustekinumab achieves remission in Crohn's diseaseUstekinumabEstablished93%15
Tofacitinib effective in moderate-to-severe ulcerative colitisJAKEstablished91%1
Combination anti-TNF plus immunomodulator beats monotherapyAnti TNFEstablished90%13
Subcutaneous vedolizumab non-inferior to intravenous in ulcerative colitisVedolizumabEstablished88%8
Upadacitinib induces and maintains remission in Crohn's diseaseJAKLikely82%1
Vedolizumab superior to adalimumab in ulcerative colitisVedolizumabLikely80%16
Mirikizumab induces and maintains ulcerative colitis remissionIl23Likely79%8
Mucosal healing reduces inflammatory bowel disease complicationsTreatment TargetsLikely79%10
Ustekinumab non-inferior to adalimumab in Crohn's diseaseUstekinumabLikely79%13
Risankizumab superior to ustekinumab in Crohn's diseaseIl23Likely78%9
JAK inhibitors increase herpes zoster riskJAKLikely78%1
Calprotectin predicts mucosal healingTreatment TargetsLikely77%1
Risankizumab induces and maintains ulcerative colitis remissionIl23Likely75%8
Mirikizumab achieves remission in Crohn's diseaseIl23Likely74%7
Vedolizumab effective in anti-TNF-failure Crohn's diseaseVedolizumabLikely71%5
Therapeutic drug monitoring improves anti-TNF loss-of-response outcomesAnti TNFLikely70%13
Top-down anti-TNF improves Crohn's disease outcomesAnti TNFUncertain58%10
Upadacitinib superior to tofacitinib in ulcerative colitisJAKUncertain57%1
Transmural healing superior target in Crohn's diseaseTreatment TargetsUncertain56%10
Ustekinumab better than vedolizumab in anti-TNF-failure Crohn's diseaseUstekinumabUncertain55%12
Upadacitinib superior to vedolizumab in ulcerative colitisPositioningUncertain54%7
IL-23 inhibitors safer than JAK inhibitorsPositioningUncertain50%8
Track Inflammatory Bowel Disease.
These claims are re-scored against new papers every week. Track this topic for the full review, including each claim’s challenge and the papers behind it.
Track this topic →
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely70–84%Well supported, with some gaps or indirect evidence.
Uncertain50–69%Mixed or limited evidence. Genuinely open.
Doubtful30–49%Little support; the weight of evidence leans against it.
Refuted< 30%The evidence contradicts it — confidently false as stated.